Skip to content
  • Who We Are
    • About Us
    • Leadership
    • Board of Directors
    • Partners
  • Our Science
    • About Our Science
    • Technology
    • Pipeline
    • Publications
  • Patients
    • Clinical Trials
    • Expanded Access
  • Careers
  • Investors
  • News
Menu
  • Who We Are
    • About Us
    • Leadership
    • Board of Directors
    • Partners
  • Our Science
    • About Our Science
    • Technology
    • Pipeline
    • Publications
  • Patients
    • Clinical Trials
    • Expanded Access
  • Careers
  • Investors
  • News
Search
Close
Contact us

Milan Mangeshkar

PhD

VP, Biometrics

Dr. Mangeshkar joined Zymeworks in January 2022 as Vice President, Biometrics. Dr. Mangeshkar brings 20+ years of experience providing oversight for all biostatics functions in multi-faceted health care organizations. Prior to joining Zymeworks Dr. Mangeshkar was at Exelixis Inc. for fourteen years where she was recognized for track record for leading successful Phase 1-4 oncology studies. Dr. Mangeshkar was a key contributor to four successful NDA/sNDA submissions to the FDA and EMA in indications that included medullary thyroid cancer, renal cell carcinoma, hepatocellular carcinoma. She has also worked in the diagnostics and devices areas. Dr. Mangeshkar holds a Ph.D. in Statistics from Virginia Tech and Master’s in Statistics from Bombay University.

Milan Mangeshkar

Milan Mangeshkar

PhD

VP, Biometrics

Dr. Mangeshkar joined Zymeworks in January 2022 as Vice President, Biometrics. Dr. Mangeshkar brings 20+ years of experience providing oversight for all biostatics functions in multi-faceted health care organizations. Prior to joining Zymeworks Dr. Mangeshkar was at Exelixis Inc. for fourteen years where she was recognized for track record for leading successful Phase 1-4 oncology studies. Dr. Mangeshkar was a key contributor to four successful NDA/sNDA submissions to the FDA and EMA in indications that included medullary thyroid cancer, renal cell carcinoma, hepatocellular carcinoma. She has also worked in the diagnostics and devices areas. Dr. Mangeshkar holds a Ph.D. in Statistics from Virginia Tech and Master’s in Statistics from Bombay University.

PhD
VP, Biometrics

Milan Mangeshkar

PhD

VP, Biometrics

Dr. Mangeshkar joined Zymeworks in January 2022 as Vice President, Biometrics. Dr. Mangeshkar brings 20+ years of experience providing oversight for all biostatics functions in multi-faceted health care organizations. Prior to joining Zymeworks Dr. Mangeshkar was at Exelixis Inc. for fourteen years where she was recognized for track record for leading successful Phase 1-4 oncology studies. Dr. Mangeshkar was a key contributor to four successful NDA/sNDA submissions to the FDA and EMA in indications that included medullary thyroid cancer, renal cell carcinoma, hepatocellular carcinoma. She has also worked in the diagnostics and devices areas. Dr. Mangeshkar holds a Ph.D. in Statistics from Virginia Tech and Master’s in Statistics from Bombay University.

Kaycia Wilde

PhD

VP, Clinical Operations

Dr. Wilde has served as VP of Clinical Operations since March 2021. Dr. Wilde is a global clinical research management professional with over 25 years’ experience in Clinical Development, including Oncology and the development of cell therapy products. Prior to joining Zymeworks, Dr. Wilde was SVP Operations at Kartos Therapeutics where she managed the Clinical Operations, Quality, CMC, Project Management and Facilities functions. Prior to that Dr. Wilde was head of Clinical Operations Europe at Kite Pharma where she built, developed, and managed EU Clinical Operations and Logistics teams through the development and successful European launch of Yescarta®. Dr. Wilde has also held various positions at AstraZeneca, Onyx Pharmaceuticals and Amgen working across multiple locations, therapeutic areas, indications and phases as well as heading up Amgen’s Global Development Operations Training, Quality and Standards team. Dr. Wilde received her BSc in Physiology and Ph.D. in Cardiac physiology from the University of Leeds, UK.

Kaycia Wilde

Kaycia Wilde

PhD

VP, Clinical Operations

Dr. Wilde has served as VP of Clinical Operations since March 2021. Dr. Wilde is a global clinical research management professional with over 25 years’ experience in Clinical Development, including Oncology and the development of cell therapy products. Prior to joining Zymeworks, Dr. Wilde was SVP Operations at Kartos Therapeutics where she managed the Clinical Operations, Quality, CMC, Project Management and Facilities functions. Prior to that Dr. Wilde was head of Clinical Operations Europe at Kite Pharma where she built, developed, and managed EU Clinical Operations and Logistics teams through the development and successful European launch of Yescarta®. Dr. Wilde has also held various positions at AstraZeneca, Onyx Pharmaceuticals and Amgen working across multiple locations, therapeutic areas, indications and phases as well as heading up Amgen’s Global Development Operations Training, Quality and Standards team. Dr. Wilde received her BSc in Physiology and Ph.D. in Cardiac physiology from the University of Leeds, UK.

PhD
VP, Clinical Operations

Kaycia Wilde

PhD

VP, Clinical Operations

Dr. Wilde has served as VP of Clinical Operations since March 2021. Dr. Wilde is a global clinical research management professional with over 25 years’ experience in Clinical Development, including Oncology and the development of cell therapy products. Prior to joining Zymeworks, Dr. Wilde was SVP Operations at Kartos Therapeutics where she managed the Clinical Operations, Quality, CMC, Project Management and Facilities functions. Prior to that Dr. Wilde was head of Clinical Operations Europe at Kite Pharma where she built, developed, and managed EU Clinical Operations and Logistics teams through the development and successful European launch of Yescarta®. Dr. Wilde has also held various positions at AstraZeneca, Onyx Pharmaceuticals and Amgen working across multiple locations, therapeutic areas, indications and phases as well as heading up Amgen’s Global Development Operations Training, Quality and Standards team. Dr. Wilde received her BSc in Physiology and Ph.D. in Cardiac physiology from the University of Leeds, UK.

John Fann

PhD

VP, Technical Operations Process Science in Technical & Manufacturing Operations

Dr. Fann joins Zymeworks with over 20 years of experience in bioprocess development and biologics manufacturing and controls. Dr. Fann started his postdoctoral career with StemCell Technologies in Vancouver, then joined Seattle Genetics in its early years. After establishing the upstream function and accomplishing the first technology transfer and clinical manufacturing for Seagen, Dr. Fann joined AbbVie Bioresearch Center. He held several leadership positions in Process Sciences and MS&T. At AbbVie, Dr. Fann experienced many clinical projects and helped to launch and scale up several commercial biotherapeutics, including the blockbuster drug Humira. Dr. Fann joined Bristol Myers Squib after returning to Seattle, as the head of M&ST and Bioprocess Development. He was leading microbial process development at BMS and accomplished several early and late-stage clinical projects. Prior to Zymeworks, Dr. Fann was VP of Bioprocess R&D at AGC Biologics, leading the global new technology development at AGC. Dr. Fann holds a Ph.D. in Chemical Engineering from the University of British Columbia.

John Fann

John Fann

PhD

VP, Technical Operations Process Science in Technical & Manufacturing Operations

Dr. Fann joins Zymeworks with over 20 years of experience in bioprocess development and biologics manufacturing and controls. Dr. Fann started his postdoctoral career with StemCell Technologies in Vancouver, then joined Seattle Genetics in its early years. After establishing the upstream function and accomplishing the first technology transfer and clinical manufacturing for Seagen, Dr. Fann joined AbbVie Bioresearch Center. He held several leadership positions in Process Sciences and MS&T. At AbbVie, Dr. Fann experienced many clinical projects and helped to launch and scale up several commercial biotherapeutics, including the blockbuster drug Humira. Dr. Fann joined Bristol Myers Squib after returning to Seattle, as the head of M&ST and Bioprocess Development. He was leading microbial process development at BMS and accomplished several early and late-stage clinical projects. Prior to Zymeworks, Dr. Fann was VP of Bioprocess R&D at AGC Biologics, leading the global new technology development at AGC. Dr. Fann holds a Ph.D. in Chemical Engineering from the University of British Columbia.

PhD
VP, Technical Operations Process Science in Technical & Manufacturing Operations

John Fann

PhD

VP, Technical Operations Process Science in Technical & Manufacturing Operations

Dr. Fann joins Zymeworks with over 20 years of experience in bioprocess development and biologics manufacturing and controls. Dr. Fann started his postdoctoral career with StemCell Technologies in Vancouver, then joined Seattle Genetics in its early years. After establishing the upstream function and accomplishing the first technology transfer and clinical manufacturing for Seagen, Dr. Fann joined AbbVie Bioresearch Center. He held several leadership positions in Process Sciences and MS&T. At AbbVie, Dr. Fann experienced many clinical projects and helped to launch and scale up several commercial biotherapeutics, including the blockbuster drug Humira. Dr. Fann joined Bristol Myers Squib after returning to Seattle, as the head of M&ST and Bioprocess Development. He was leading microbial process development at BMS and accomplished several early and late-stage clinical projects. Prior to Zymeworks, Dr. Fann was VP of Bioprocess R&D at AGC Biologics, leading the global new technology development at AGC. Dr. Fann holds a Ph.D. in Chemical Engineering from the University of British Columbia.

Mark Hollywood

Executive Vice President and Head of Technical and Manufacturing Operations

Mr. Hollywood joined Zymeworks in 2019 and currently serves as our Executive Vice President and Head of Technical and Manufacturing Operations. Mr. Hollywood brings over 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics (a Bristol-Myers Squibb company), where he oversaw biologics development, manufacturing, quality, and supply chain operations. He joined ZymoGenetics in 2010 and led technical operations for a portfolio of clinical and commercial products, and was responsible for building and managing a multi-host drug substance manufacturing facility. Mr. Hollywood brings a wealth of experience in operations management, having held positions of increasing responsibility in process science, manufacturing, quality, and regulatory compliance at organizations including Amgen, Dendreon and Centeon (a Rhone-Poulenc Rorer and Hoescht company). Mr. Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University.

Mark Hollywood

Mark Hollywood

Executive Vice President and Head of Technical and Manufacturing Operations

Mr. Hollywood joined Zymeworks in 2019 and currently serves as our Executive Vice President and Head of Technical and Manufacturing Operations. Mr. Hollywood brings over 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics (a Bristol-Myers Squibb company), where he oversaw biologics development, manufacturing, quality, and supply chain operations. He joined ZymoGenetics in 2010 and led technical operations for a portfolio of clinical and commercial products, and was responsible for building and managing a multi-host drug substance manufacturing facility. Mr. Hollywood brings a wealth of experience in operations management, having held positions of increasing responsibility in process science, manufacturing, quality, and regulatory compliance at organizations including Amgen, Dendreon and Centeon (a Rhone-Poulenc Rorer and Hoescht company). Mr. Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University.

Executive Vice President and Head of Technical and Manufacturing Operations

Mark Hollywood

Executive Vice President and Head of Technical and Manufacturing Operations

Mr. Hollywood joined Zymeworks in 2019 and currently serves as our Executive Vice President and Head of Technical and Manufacturing Operations. Mr. Hollywood brings over 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics (a Bristol-Myers Squibb company), where he oversaw biologics development, manufacturing, quality, and supply chain operations. He joined ZymoGenetics in 2010 and led technical operations for a portfolio of clinical and commercial products, and was responsible for building and managing a multi-host drug substance manufacturing facility. Mr. Hollywood brings a wealth of experience in operations management, having held positions of increasing responsibility in process science, manufacturing, quality, and regulatory compliance at organizations including Amgen, Dendreon and Centeon (a Rhone-Poulenc Rorer and Hoescht company). Mr. Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University.

Chris Astle

PhD

SVP & Chief Financial Officer

Dr. Astle joined Zymeworks in April 2021 and currently serves as Senior Vice President and Chief Financial Officer. Prior to joining Zymeworks, Dr. Astle worked as a Chief Financial Officer at the CFO Centre in British Columbia, Canada from March 2020 to March 2021, and as Vice President, Finance at Alder BioPharmaceuticals Inc. in Seattle, Washington from April 2019 to February 2020. From August 2017 to January 2020, he served as Chief Executive Officer and founder of Think Forwards, a boutique financial consulting firm in London, UK. Dr. Astle worked at Allergan from 2011 to 2017, including as the Associate Vice President Finance, International Division from July 2016 to July 2017, managing multiple product launches, M&A transactions and restructurings, with a team of 170 across 60 countries. He is a UK Chartered Accountant (ICAS), qualifying at PwC London, UK in Audit & Pharmaceutical Performance Improvement Consulting with audit clients including GSK. Dr. Astle serves as a member of the board of directors of two private biotechnology companies, Oak Bay Biosciences (2020-present) and Healome Therapeutics (2021-present). During his time in the UK, he was the Chair of the 2018 CFO Agenda conference, guest lecturer at the Henley Business School, and judge at the British Accountancy Awards. Dr. Astle holds a PhD in Organic Chemistry from the University of Bristol (UK) and a MChem in Chemistry from the University of Liverpool (UK) and is also a certified ski instructor.

Chris Astle

Chris Astle

PhD

SVP & Chief Financial Officer

Dr. Astle joined Zymeworks in April 2021 and currently serves as Senior Vice President and Chief Financial Officer. Prior to joining Zymeworks, Dr. Astle worked as a Chief Financial Officer at the CFO Centre in British Columbia, Canada from March 2020 to March 2021, and as Vice President, Finance at Alder BioPharmaceuticals Inc. in Seattle, Washington from April 2019 to February 2020. From August 2017 to January 2020, he served as Chief Executive Officer and founder of Think Forwards, a boutique financial consulting firm in London, UK. Dr. Astle worked at Allergan from 2011 to 2017, including as the Associate Vice President Finance, International Division from July 2016 to July 2017, managing multiple product launches, M&A transactions and restructurings, with a team of 170 across 60 countries. He is a UK Chartered Accountant (ICAS), qualifying at PwC London, UK in Audit & Pharmaceutical Performance Improvement Consulting with audit clients including GSK. Dr. Astle serves as a member of the board of directors of two private biotechnology companies, Oak Bay Biosciences (2020-present) and Healome Therapeutics (2021-present). During his time in the UK, he was the Chair of the 2018 CFO Agenda conference, guest lecturer at the Henley Business School, and judge at the British Accountancy Awards. Dr. Astle holds a PhD in Organic Chemistry from the University of Bristol (UK) and a MChem in Chemistry from the University of Liverpool (UK) and is also a certified ski instructor.

PhD
SVP & Chief Financial Officer

Chris Astle

PhD

SVP & Chief Financial Officer

Dr. Astle joined Zymeworks in April 2021 and currently serves as Senior Vice President and Chief Financial Officer. Prior to joining Zymeworks, Dr. Astle worked as a Chief Financial Officer at the CFO Centre in British Columbia, Canada from March 2020 to March 2021, and as Vice President, Finance at Alder BioPharmaceuticals Inc. in Seattle, Washington from April 2019 to February 2020. From August 2017 to January 2020, he served as Chief Executive Officer and founder of Think Forwards, a boutique financial consulting firm in London, UK. Dr. Astle worked at Allergan from 2011 to 2017, including as the Associate Vice President Finance, International Division from July 2016 to July 2017, managing multiple product launches, M&A transactions and restructurings, with a team of 170 across 60 countries. He is a UK Chartered Accountant (ICAS), qualifying at PwC London, UK in Audit & Pharmaceutical Performance Improvement Consulting with audit clients including GSK. Dr. Astle serves as a member of the board of directors of two private biotechnology companies, Oak Bay Biosciences (2020-present) and Healome Therapeutics (2021-present). During his time in the UK, he was the Chair of the 2018 CFO Agenda conference, guest lecturer at the Henley Business School, and judge at the British Accountancy Awards. Dr. Astle holds a PhD in Organic Chemistry from the University of Bristol (UK) and a MChem in Chemistry from the University of Liverpool (UK) and is also a certified ski instructor.

Jeffrey Smith

MD, FRCP

SVP, Early-Stage Development

Dr. Smith joined Zymeworks in January 2023 and currently serves as our Senior Vice President of Early-Stage Development based at our European hub in Dublin, Ireland . Dr. Smith has held many senior positions within the pharmaceutical industry, most recently, Managing Director of Alder Biopharmaceuticals Inc. Dublin, Ireland and before that Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc, Seattle. Dr. Smith was responsible for the clinical development (phase I – III) of eptinezumab (anti-CGRP antibody for migraine) and clazakizumab (anti -IL-6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceutcials Inc (founded 2004). Dr. Smith received his MB BS and MD from the University of London, UK.

Jeffrey Smith

Jeffrey Smith

MD, FRCP

SVP, Early-Stage Development

Dr. Smith joined Zymeworks in January 2023 and currently serves as our Senior Vice President of Early-Stage Development based at our European hub in Dublin, Ireland . Dr. Smith has held many senior positions within the pharmaceutical industry, most recently, Managing Director of Alder Biopharmaceuticals Inc. Dublin, Ireland and before that Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc, Seattle. Dr. Smith was responsible for the clinical development (phase I – III) of eptinezumab (anti-CGRP antibody for migraine) and clazakizumab (anti -IL-6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceutcials Inc (founded 2004). Dr. Smith received his MB BS and MD from the University of London, UK.

MD, FRCP
SVP, Early-Stage Development

Jeffrey Smith

MD, FRCP

SVP, Early-Stage Development

Dr. Smith joined Zymeworks in January 2023 and currently serves as our Senior Vice President of Early-Stage Development based at our European hub in Dublin, Ireland . Dr. Smith has held many senior positions within the pharmaceutical industry, most recently, Managing Director of Alder Biopharmaceuticals Inc. Dublin, Ireland and before that Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc, Seattle. Dr. Smith was responsible for the clinical development (phase I – III) of eptinezumab (anti-CGRP antibody for migraine) and clazakizumab (anti -IL-6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceutcials Inc (founded 2004). Dr. Smith received his MB BS and MD from the University of London, UK.

Daniel Dex

JD

SVP, Corporate Secretary and General Counsel

Mr. Dex joined Zymeworks in September 2017, and currently serves as our Senior Vice President, Corporate Secretary and General Counsel. Mr. Dex brings over 25 years of diverse legal experience to Zymeworks, having worked in private practice at prominent law firms in both the U.S. and Canada, in-house with Avigilon Corporation (a Motorola Solutions company) and the New York Public Library, and with the U.S. federal district court for the Eastern District of Pennsylvania. Mr. Dex received a J.D. from the University of Pennsylvania Law School and a B.A. from Brown University. He is a member of the bars of both New York and British Columbia.

Daniel Dex

Daniel Dex

JD

SVP, Corporate Secretary and General Counsel

Mr. Dex joined Zymeworks in September 2017, and currently serves as our Senior Vice President, Corporate Secretary and General Counsel. Mr. Dex brings over 25 years of diverse legal experience to Zymeworks, having worked in private practice at prominent law firms in both the U.S. and Canada, in-house with Avigilon Corporation (a Motorola Solutions company) and the New York Public Library, and with the U.S. federal district court for the Eastern District of Pennsylvania. Mr. Dex received a J.D. from the University of Pennsylvania Law School and a B.A. from Brown University. He is a member of the bars of both New York and British Columbia.

JD
SVP, Corporate Secretary and General Counsel

Daniel Dex

JD

SVP, Corporate Secretary and General Counsel

Mr. Dex joined Zymeworks in September 2017, and currently serves as our Senior Vice President, Corporate Secretary and General Counsel. Mr. Dex brings over 25 years of diverse legal experience to Zymeworks, having worked in private practice at prominent law firms in both the U.S. and Canada, in-house with Avigilon Corporation (a Motorola Solutions company) and the New York Public Library, and with the U.S. federal district court for the Eastern District of Pennsylvania. Mr. Dex received a J.D. from the University of Pennsylvania Law School and a B.A. from Brown University. He is a member of the bars of both New York and British Columbia.

Paul Moore

PhD

Chief Scientific Officer

Dr. Moore joined Zymeworks in July 2022 and currently serves as our Chief Scientific Officer. Dr. Moore brings over 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. Prior to joining Zymeworks, Paul served as Vice President, Cell Biology, and Immunology at MacroGenics, where he worked on the development of numerous clinical stage compounds and scientific collaborations with a range of pharmaceutical partners, including Pfizer, Servier, Gilead, Takeda, Janssen, Roche and Zai Labs. Prior to joining MacroGenics, he was Director of Cell Biology at Celera where he oversaw research efforts to develop novel antibody-based therapeutics. Dr. Moore received a Ph.D. in molecular genetics from the University of Glasgow. He has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents.

Paul Moore

Paul Moore

PhD

Chief Scientific Officer

Dr. Moore joined Zymeworks in July 2022 and currently serves as our Chief Scientific Officer. Dr. Moore brings over 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. Prior to joining Zymeworks, Paul served as Vice President, Cell Biology, and Immunology at MacroGenics, where he worked on the development of numerous clinical stage compounds and scientific collaborations with a range of pharmaceutical partners, including Pfizer, Servier, Gilead, Takeda, Janssen, Roche and Zai Labs. Prior to joining MacroGenics, he was Director of Cell Biology at Celera where he oversaw research efforts to develop novel antibody-based therapeutics. Dr. Moore received a Ph.D. in molecular genetics from the University of Glasgow. He has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents.

PhD
Chief Scientific Officer

Paul Moore

PhD

Chief Scientific Officer

Dr. Moore joined Zymeworks in July 2022 and currently serves as our Chief Scientific Officer. Dr. Moore brings over 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. Prior to joining Zymeworks, Paul served as Vice President, Cell Biology, and Immunology at MacroGenics, where he worked on the development of numerous clinical stage compounds and scientific collaborations with a range of pharmaceutical partners, including Pfizer, Servier, Gilead, Takeda, Janssen, Roche and Zai Labs. Prior to joining MacroGenics, he was Director of Cell Biology at Celera where he oversaw research efforts to develop novel antibody-based therapeutics. Dr. Moore received a Ph.D. in molecular genetics from the University of Glasgow. He has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents.

Neil Klompas

CPA, CA

President and Chief Operating Officer

Mr. Klompas joined Zymeworks in March 2007 and currently serves as our President and Chief Operating Officer. Mr. Klompas served as Zymeworks’ Chief Financial Officer from 2007 to 2022. Prior to joining Zymeworks, he worked with KPMG LLP in Canada and the United States, most recently (from 2005 to 2007) with KPMG’s Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice in Princeton, New Jersey, where he advised on transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, from 2000 to 2005 Mr. Klompas worked with KPMG’s Canadian Biotechnology and Pharmaceuticals practice. Mr. Klompas currently serves on the board of directors of Liminal BioSciences Inc. (NASDAQ: LMNL). Mr. Klompas is a Chartered Professional Accountant and is a member of the Chartered Professional Accountants of British Columbia. Mr. Klompas also holds a degree in Microbiology & Immunology from the University of British Columbia

Neil Klompas

Neil Klompas

CPA, CA

President and Chief Operating Officer

Mr. Klompas joined Zymeworks in March 2007 and currently serves as our President and Chief Operating Officer. Mr. Klompas served as Zymeworks’ Chief Financial Officer from 2007 to 2022. Prior to joining Zymeworks, he worked with KPMG LLP in Canada and the United States, most recently (from 2005 to 2007) with KPMG’s Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice in Princeton, New Jersey, where he advised on transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, from 2000 to 2005 Mr. Klompas worked with KPMG’s Canadian Biotechnology and Pharmaceuticals practice. Mr. Klompas currently serves on the board of directors of Liminal BioSciences Inc. (NASDAQ: LMNL). Mr. Klompas is a Chartered Professional Accountant and is a member of the Chartered Professional Accountants of British Columbia. Mr. Klompas also holds a degree in Microbiology & Immunology from the University of British Columbia

CPA, CA
President and Chief Operating Officer

Neil Klompas

CPA, CA

President and Chief Operating Officer

Mr. Klompas joined Zymeworks in March 2007 and currently serves as our President and Chief Operating Officer. Mr. Klompas served as Zymeworks’ Chief Financial Officer from 2007 to 2022. Prior to joining Zymeworks, he worked with KPMG LLP in Canada and the United States, most recently (from 2005 to 2007) with KPMG’s Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice in Princeton, New Jersey, where he advised on transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, from 2000 to 2005 Mr. Klompas worked with KPMG’s Canadian Biotechnology and Pharmaceuticals practice. Mr. Klompas currently serves on the board of directors of Liminal BioSciences Inc. (NASDAQ: LMNL). Mr. Klompas is a Chartered Professional Accountant and is a member of the Chartered Professional Accountants of British Columbia. Mr. Klompas also holds a degree in Microbiology & Immunology from the University of British Columbia

Kenneth Galbraith

Chair & CEO

Mr. Galbraith has served as Zymeworks’ Chair & CEO since January 2022. Mr. Galbraith has over 35 years’ experience in biotechnology and venture capital having acted as an executive, director, investor as well as an advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors across North America and the UK in the growth of both private and public companies from an early-stage through regulatory approval and commercialization. Ken has worked with many biotechnology companies including: Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals among others. Mr. Galbraith currently serves on the board of directors of Profound Medical and Kalium Health. He earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985.

Kenneth Galbraith

Kenneth Galbraith

Chair & CEO

Mr. Galbraith has served as Zymeworks’ Chair & CEO since January 2022. Mr. Galbraith has over 35 years’ experience in biotechnology and venture capital having acted as an executive, director, investor as well as an advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors across North America and the UK in the growth of both private and public companies from an early-stage through regulatory approval and commercialization. Ken has worked with many biotechnology companies including: Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals among others. Mr. Galbraith currently serves on the board of directors of Profound Medical and Kalium Health. He earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985.

Chair & CEO

Kenneth Galbraith

Chair & CEO

Mr. Galbraith has served as Zymeworks’ Chair & CEO since January 2022. Mr. Galbraith has over 35 years’ experience in biotechnology and venture capital having acted as an executive, director, investor as well as an advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors across North America and the UK in the growth of both private and public companies from an early-stage through regulatory approval and commercialization. Ken has worked with many biotechnology companies including: Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals among others. Mr. Galbraith currently serves on the board of directors of Profound Medical and Kalium Health. He earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985.

Twitter Linkedin-in
©2023, Zymeworks Inc.

Who we are

  • About Us
  • Leadership
  • Board of Directors
  • Partners
Menu
  • About Us
  • Leadership
  • Board of Directors
  • Partners

Our Science

  • About Our Science
  • Our Technology
  • Our Pipeline
Menu
  • About Our Science
  • Our Technology
  • Our Pipeline

Patients

  • Our Patients
  • Clinical Trials
  • Expanded Access
Menu
  • Our Patients
  • Clinical Trials
  • Expanded Access

Corporate

  • Careers
  • Terms of Use
  • Privacy Policy
  • Contact
Menu
  • Careers
  • Terms of Use
  • Privacy Policy
  • Contact
Manage Cookie Consent
This website uses cookies to ensure you get the best experience on our website. Learn more.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}